Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Fineline Cube Apr 13, 2026
Company Deals

Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio

Fineline Cube Apr 13, 2026
Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Fineline Cube Apr 12, 2026
Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Fineline Cube Apr 12, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Deals

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

Fineline Cube Mar 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Policy / Regulatory

China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces

Fineline Cube Mar 20, 2024

The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...

Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

Fineline Cube Mar 20, 2024

Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...

Company Drug

Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...

Company

Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up

Fineline Cube Mar 20, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...

Company Deals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Fineline Cube Mar 20, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...

Company

China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements

Fineline Cube Mar 20, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...

Company Drug

Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin

Fineline Cube Mar 20, 2024

Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...

Company Drug

Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial

Fineline Cube Mar 20, 2024

Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...

Company Drug

China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis

Fineline Cube Mar 20, 2024

China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...

Company Drug

AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage...

Policy / Regulatory

China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal

Fineline Cube Mar 19, 2024

The National Joint Procurement Office in China has released a notification outlining the information and...

Company

WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles

Fineline Cube Mar 19, 2024

WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...

Company Drug

Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug...

Company Drug

Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...

Policy / Regulatory

CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...

Company Drug

AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...

Posts pagination

1 … 370 371 372 … 649

Recent updates

  • Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
  • Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology
  • Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio
  • Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
  • Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech

Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Company Deals

Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio

Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.